4
MARKET OVERVIEW
Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
THREAT OF NEW ENTRANTS
5.1.2
THREAT OF SUBSTITUTES
5.1.3
BARGAINING POWER OF SUPPLIERS
5.1.4
BARGAINING POWER OF BUYERS
5.1.5
INTENSITY OF COMPETITION RIVALRY
5.2
MACROECONOMIC OUTLOOK
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4
TRENDS IN GLOBAL PHARMA INDUSTRY
5.5.1
AVERAGE SELLING PRICE OF HUMAN MICROBIOME DRUGS, BY END-USE INDUSTRY,
5.5.2
AVERAGE SELLING PRICE TREND OF HUMAN MICROBIOME DRUGS, BY DRUGS, 2022-2024
5.5.3
AVERAGE SELLING PRICE TREND OF HUMAN MICROBIOME DRUGS, BY REGION, 2022-2024
5.6
KEY CONFERENCES & EVENTS, 2025-2026
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS
5.7.1
DISRUPTION INDEX: MARKET READINESS VS. ADOPTION VS. MATURITY
5.8
INVESTMENT AND FUNDING SCENARIO
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1.1
WHOLE-GENOME SEQUENCING
6.1.2
16S RNA SEQUENCING METHOD
6.1.3
NANOPORE SEQUENCING
6.2
COMPLEMENTARY TECHNOLOGIES
6.2.1
METATRANSCRIPTOMICS
6.3
ADJACENT TECHNOLOGIES
6.7
IMPACT OF AI/ GEN AI ON HUMAN MICROBIOME DRUGS MARKET
6.7.1
TOP USE CASES AND MARKET POTENTIAL
6.7.2
BEST PRACTICES IN AI-ENABLED HUMAN MICROBIOME WORKFLOWS
6.7.3
CASE STUDIES OF AI ADOPTION IN HUMAN MICROBIOME DRUGS MARKET
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.7.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED MICROBIOME ANALYTICS SOLUTIONS
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.2
DECISION-MAKING PROCESS
8.3
KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.3.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.4
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.5
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
HUMAN MICROBIOME DRUGS MARKET, BY TYPE, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF KEY DRUGS, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
9.2
LIVE BIOTHERAPEUTIC PRODUCTS (LBPS)
9.3
FECAL MICROBIOTA–DERIVED THERAPEUTICS
9.4
ENGINEERED MICROBIAL THERAPEUTICS
9.5
MICROBIOME-MODULATING SMALL MOLECULES
10
HUMAN MICROBIOME DRUGS MARKET, BY DISEASE, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF DISEASES, THEIR MARKET POTENTIAL, AND REVENUE TRENDS
10.2
GASTROINTESTINAL DISEASES
11
HUMAN MICROBIOME DRUGS MARKET, BY ROUTE OF ADMINISTRATION, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT ROUTES OF ADMINISTRATION, MARKET POTENTIAL ACROSS CUSTOMERS
11.2
ORAL ROUTE OF ADMINISTRATION
11.3
RECTAL ROUTE OF ADMINISTRATION
12
HUMAN MICROBIOME DRUGS MARKET, BY END USER, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
COMPARATIVE ASSESSMENT OF DEMAND PATTERNS, MARKET POTENTIAL ACROSS CUSTOMERS
12.3
LONG-TERM CARE FACILITIES
13
HUMAN MICROBIOME DRUGS MARKET, BY REGION, (MARKET SIZE, 2023 - 2031 – IN VALUE, USD MILLION)
ASSESSMENT OF GROWTH PATTERNS, INDUSTRY FORCES, REGULATORY LANDSCAPE, AND MARKET POTENTIAL ACROSS KEY COUNTRIES
13.5.3
REST OF LATIN AMERICA
13.6.1.1
KINGDOM OF SAUDI ARABIA
13.6.1.3
REST OF GCC COUNTRIES
13.6.2
REST OF MIDDLE EAST
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
14.2
KEY PLAYERS’ STRATEGIES/RIGHT TO WIN, JANUARY 2022–NOVEMBER
14.3
REVENUE ANALYSIS, 2020-2024
14.4
MARKET SHARE ANALYSIS,
14.5
COMPANY EVALUATION MATRIX: KEY PLAYERS,
14.5.5
COMPANY FOOTPRINT: KEY PLAYERS,
14.5.5.1
COMPANY FOOTPRINT
14.5.5.2
REGION FOOTPRINT
14.5.5.4
DISEASE FOOTPRINT
14.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
14.6.1
PROGRESSIVE COMPANIES
14.6.2
RESPONSIVE COMPANIES
14.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
14.6.5.1
DETAILED LIST OF KEY STARTUPS/ SMES
14.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
14.7
COMPETITIVE SCENARIO
14.8.1
SERES THERAPEUTICS
14.9
COMPANY VALUATION AND FINANCIAL METRICS
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE HUMAN MICROBIOME DRUGS MARKET LANDSCAPE
15.1.1
SERES THERAPEUTICS
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
PRODUCTS OFFERED
15.1.1.3.1
KEY STRENGTHS/RIGHT TO WIN
15.1.1.3.2
STRATEGIC CHOICES
15.1.1.3.3
WEAKNESSES/COMPETITIVE THREATS
15.1.2.1
BUSINESS OVERVIEW
15.1.2.2
PRODUCTS OFFERED
15.1.2.3.1
KEY STRENGTHS/RIGHT TO WIN
15.1.2.3.2
STRATEGIC CHOICES
15.1.2.3.3
WEAKNESSES/COMPETITIVE THREATS
15.1.3.1
BUSINESS OVERVIEW
15.1.3.2
PRODUCTS OFFERED
15.1.3.3.1
KEY STRENGTHS/RIGHT TO WIN
15.1.3.3.2
STRATEGIC CHOICES
15.1.3.3.3
WEAKNESSES/COMPETITIVE THREATS
15.1.4.1
BUSINESS OVERVIEW
15.1.4.2
PRODUCTS OFFERED
15.1.4.3.1
KEY STRENGTHS/RIGHT TO WIN
15.1.4.3.2
STRATEGIC CHOICES
15.1.4.3.3
WEAKNESSES/COMPETITIVE THREATS
15.1.5
INFANT BACTERIAL THERAPEUTICS AB
15.1.5.1
BUSINESS OVERVIEW
15.1.5.2
PRODUCTS OFFERED
15.1.5.3.1
KEY STRENGTHS/RIGHT TO WIN
15.1.5.3.2
STRATEGIC CHOICES
15.1.5.3.3
WEAKNESSES/COMPETITIVE THREATS
15.1.6
FINCH THERAPEUTICS GROUP, INC.
15.1.6.1
BUSINESS OVERVIEW
15.1.6.2
PRODUCTS OFFERED
15.1.6.3
RECENT DEVELOPMENTS
15.1.7.1
BUSINESS OVERVIEW
15.1.7.2
PRODUCTS OFFERED
15.1.7.3
RECENT DEVELOPMENTS
15.1.8.1
BUSINESS OVERVIEW
15.1.8.2
PRODUCTS OFFERED
15.1.8.3
RECENT DEVELOPMENTS
16.1.1.1
KEY SOURCES OF SECONDARY DATA
16.1.1.2
KEY OBJECTIVES OF SECONDARY DATA
16.1.2.1
BREAKDOWN OF PRIMARIES
16.1.2.2
KEY OBJECTIVES OF PRIMARY RESEARCH
16.2
MARKET SIZE ESTIMATION
16.2.1
GLOBAL HUMAN MICROBIOME DRUGS MARKET SIZE ESTIMATION,
16.2.1.1
COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
16.2.1.2
MNM REPOSITORY ANALYSIS
16.2.1.3
SECONDARY ANALYSIS
16.2.1.4
PRIMARY RESEARCH
16.2.1.4.1
INSIGHTS FROM PRIMARY EXPERTS
16.2.2
SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
16.3
MARKET GROWTH RATE PROJECTIONS
16.6
RESEARCH LIMITATIONS & RISK ASSESSMENT
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in Human Microbiome Drugs Market